# US 2016/0250307 A1 · Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250307 A1
- Document ID: US20160250307A1
- Status: Published application
- Kind: A1
- Application number: 14/975,952
- Filed: 2015-12-21
- Published: 2016-09-01
- Earliest claimed: 2014-12-23
- Assignees: Immatics Biotechnologies GmbH
- Applicants: Immatics Biotechnologies GmbH
- Inventors: Toni Weinschenk; Andrea Mahr; Jens Fritsche; Phillip Mueller; Anita Wiebe; Sara Kutscher
- Web page: https://patentgrep.com/patent/US20160250307A1

## CPC

- A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55})
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/0011: {Cancer antigens}
- A61K 39/00111: {Hepatocyte growth factor receptor [HGFR or c-met]}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/04: Immunostimulants
- C07K 7/00: Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/435: from animals; from humans
- C07K 16/18: against material from animals or humans
- C12N 5/0636: {T lymphocytes}
- G01N 33/6803: {General methods of protein analysis not limited to specific proteins or families of proteins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 51/1057: {the tumor cell being from liver or pancreas}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 2310/16: Aptamers
- C12N 2501/998: Proteins not provided for elsewhere
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.

## Claims

### Claim 1

A peptide comprising an amino acid sequence selected from the group of SEQ ID No. 1 to SEQ ID No. 300, and/or a variant sequence thereof which is at least 88% homologous to SEQ ID No. 1 to SEQ ID No. 300, and wherein said variant binds to MHC and/or induces T cells cross-reacting with said variant peptide; and/or a pharmaceutical acceptable salt thereof, wherein said peptide, variant and/or salt is not a full-length polypeptide and further wherein said peptide, variant or salt is optionally modified and/or includes non-peptide bonds.

### Claim 2 (depends on 1)

The peptide, variant and/or salt according to claim 1, wherein said peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or -II, and wherein said peptide, when bound to MHC, is capable of being recognized by CD4 and/or CD8 T cells.

### Claim 3 (depends on 1)

The peptide and/or variant and/or salt thereof according to claim 1, wherein the amino acid sequence thereof comprises a continuous stretch of amino acids according the group of SEQ ID No. 1 to SEQ ID No. 300.

### Claim 4 (depends on 1)

The peptide and/or variant and/or salt thereof according to claim 1, wherein said peptide or variant or salt thereof has an overall length of from 8 to 100, optionally from 8 to 30, and optionally from 8 to 16 amino acids, and optionally wherein the peptide consists or consists essentially of an amino acid sequence according to SEQ ID No. 1 to SEQ ID No. 300.

### Claim 5 (depends on 1)

The peptide or variant and/or salt thereof according to any of claim 1, wherein said peptide is modified and/or includes non-peptide bonds.

### Claim 6 (depends on 1)

The peptide or variant or salt thereof according to claim 1, wherein said peptide is part of a fusion protein, optionally comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).

### Claim 7 (depends on 1)

A nucleic acid, encoding a peptide or variant or salt thereof according to claim 1, optionally linked to a heterologous promoter sequence.

### Claim 8 (depends on 7)

An expression vector capable of expressing the nucleic acid according to claim 7.

### Claim 9 (depends on 1)

The peptide or variant or salt thereof according to claim 1, capable of being used in medicine.

### Claim 10 (depends on 1)

A host cell comprising the peptide, variant or salt according to claim 1, wherein said host cell preferably is an antigen presenting cell optionally comprising a dendritic cell.

### Claim 11 (depends on 1)

A method for producing the peptide or variant thereof according to claim 1, the method comprising culturing a host cell that presents the peptide or variant thereof, and isolating the peptide or variant or salt thereof from the host cell or a culture medium.

### Claim 12 (depends on 1)

An in vitro method for producing activated T lymphocytes, the method comprising contacting in vitro one or more T cells with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said T cells in an antigen specific manner, wherein said antigen is a peptide, variant or salt according to claim 1.

### Claim 13 (depends on 12)

An activated T cell, produced by the method according to claim 12, that selectively recognizes a cell which presents a polypeptide comprising an amino acid sequence that is at least 88% homologous to SEQ ID No. 1 to SEQ ID No. 300.

### Claim 14 (depends on 13)

A method for killing target cells in a patient which target cells present a polypeptide comprising an amino acid sequence that is at least 88% homologous to SEQ ID No. 1 to SEQ ID No. 300, the method comprising administering to the patient an effective number of activated T cells as defined in claim 13.

### Claim 15 (depends on 1)

An antibody, soluble or membrane-bound, that specifically recognizes the peptide or variant or salt thereof according to claim 1, optionally the peptide or variant or salt thereof is bound to an MHC molecule and optionally the antibody carries a further effector function optionally comprising an immune stimulating domain or toxin.

### Claim 16 (depends on 1)

A peptide, variant or salt according to claim 1 capable of being used for treatment of cancer and/or in the manufacture of a medicament against cancer.

### Claim 17 (depends on 16)

The peptide, variant or salt according to claim 16, wherein said cancer is selected from the group of HCC, brain cancer, kidney cancer, pancreatic cancer, colon or rectal cancer or leukemia and other tumors that show an overexpression of most preferably APOB, FASN, COPA, preferably GLUL, GPAM, PLIN2, SLC16A1, SLC9A3R1, PCBD1, SEC16A, AKR1C4, ABCB11, HAL, CYP2E1, C4A, C4B, ALDH1L1, CRP, ACSL4, EEF2, HLTF, FBXO22, GALK1, TMCO1, TMEM33, ZNF318, IPO9, AMACR, C1QTNF3, CYP4F8, CYP4F3, CYP4F11, CYP4F12, CYP4F2, MOCOS, A1CF, COL18A1, HPR, LBP, C19orf80, CFHR5, ITIH4, TMEM110, LARP4, LMF2, SLC10A5, SLC16A11, and still preferably ANKFY1, C12orf44, C16orf58, CPSF1, DCAF8, PEX19, DDX11, DDX12P, DECR2, NME4, DENND5B, DYM, EDC4, ERI3, FAM20A, FNDC3A, GPR107, GYG2, HEATR2, IFT81, KCTD3, SHKBP1, KIAA1324L, KLHL24, MARCH6, MBTPS2, MIR1279, CPSF6, NOC4L, NXF1, PANK2, PCNXL3, PIPSL, PSMD4, PSMD14, SLC35B1, TCP11L2, THNSL2, THOC2, TOMM5, TRAPPC6B, TRIM54, TRIM55, TRIM63, UGGT2, URB1, VPS54, WIZ, ZNF45, RFTN2, SCFD1, SERINC5, CCT7P2, CMAS, ANKS1A, C17orf70, CCT7, CDK5RAP2, CLPTM1, and another protein from which a peptide SEQ ID No. 1 to SEQ ID No. 300 is derived from.

### Claim 18 (depends on 1)

A kit comprising:
(a) a container comprising a pharmaceutical composition containing the peptide(s) or the variant or salt according to claim 1 in solution or in lyophilized form;
(b) optionally, a second container containing a diluent or reconstituting solution for the lyophilized formulation;
(c) optionally, at least one more peptide selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 346, and
(d) optionally, instructions for (i) use of the solution or (ii) reconstitution and/or use of the lyophilized formulation.

### Claim 19 (depends on 18)

The kit according to claim 18, further comprising one or more of (iii) a buffer, (iv) a diluent, (v) a filter, (vi) a needle, or (v) a syringe.

### Claim 20 (depends on 18)

The kit according to claim 18, wherein said peptide is selected from the group consisting SEQ ID No. 1 to SEQ ID No. 300.

### Claim 21

A method for producing a personalized anti-cancer vaccine for a compound-based and/or cellular therapy for an individual patient, said method comprising:
a) identifying tumor-associated peptides (TUMAPs) presented by a tumor sample from the individual patient;
b) comparing the peptides as identified in a) with a warehouse of peptides that have been prescreened for immunogenicity and/or over-presentation in tumors as compared to normal tissues
c) selecting at least one peptide from the warehouse that matches a tumor-associated peptide identified in the patient; and
d) manufacturing the personalized vaccine or compound-based or cellular therapy product based on step c).

### Claim 22 (depends on 21)

The method according to claim 21, wherein said TUMAPs are identified by:
a1) comparing expression data from the tumor sample to expression data from a sample of normal tissue corresponding to the tissue type of the tumor sample to identify proteins that are over-expressed or aberrantly expressed in the tumor sample; and
a2) correlating the expression data with sequences of MHC ligands bound to MHC class I and/or class II molecules in the tumor sample to identify MHC ligands derived from proteins over-expressed or aberrantly expressed by the tumor.

### Claim 23 (depends on 21)

The method according to claim 21, wherein the sequences of MHC ligands are identified by eluting bound peptides from MHC molecules isolated from the tumor sample, and sequencing the eluted ligands.

### Claim 24 (depends on 21)

The method according to claim 21, wherein the normal tissue corresponding to the tissue type of the tumor sample is obtained from the same patient.

### Claim 25 (depends on 21)

The method according to claim 21, wherein the peptides included in the warehouse are identified based on the following steps:
aa. Performing genome-wide messenger ribonucleic acid (mRNA) expression analysis by highly parallel methods, optionally comprising microarrays or sequencing-based expression profiling, comprising identify genes that over-expressed in a malignant tissue, compared with a normal tissue or tissues;
ab. Selecting peptides encoded by selectively expressed or over-expressed genes as detected in step aa, and
ac. Determining an induction of in vivo T-cell responses by the peptides as selected comprising in vitro immunogenicity assays using human T cells from healthy donors or said patient; or
ba. Identifying HLA ligands from said tumor sample using mass spectrometry;
bb. Performing genome-wide messenger ribonucleic acid (mRNA) expression analysis by highly parallel methods, optionally comprising microarrays or sequencing-based expression profiling, comprising identify genes that over-expressed in a malignant tissue, compared with a normal tissue or tissues;
bc. Comparing the identified HLA ligands to said gene expression data;
bd. Selecting peptides encoded by selectively expressed or over-expressed genes as detected in step bc;
be. Re-detecting of selected TUMAPs from step bd on tumor tissue and lack of or infrequent detection on healthy tissues and confirming the relevance of over-expression at the mRNA level; and
bf. Determining an induction of in vivo T-cell responses by the peptides as selected comprising in vitro immunogenicity assays using human T cells from healthy donors or said patient.

### Claim 26 (depends on 21)

The method according to claim 21, wherein the immunogenicity of the peptides included in the warehouse is determined by a method comprising in vitro immunogenicity assays, patient immunomonitoring for individual HLA binding, MHC multimer staining, ELISPOT assays and/or intracellular cytokine staining.

### Claim 27 (depends on 21)

The method according to claim 21, wherein said warehouse comprises a plurality of peptides selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 346.

### Claim 28 (depends on 21)

The method according to claim 21, further comprising identifying at least one mutation that is unique to the tumor sample relative to normal corresponding tissue from the individual patient, and selecting a peptide that correlates with the mutation for inclusion in the vaccine or for the generation of cellular therapies.

### Claim 29 (depends on 28)

The method according to claim 28, wherein said at least one mutation is identified by whole genome sequencing.

### Claim 30

A T-cell receptor, soluble or membrane-bound, that is reactive with an HLA ligand, wherein said ligand has at least 75% identity to an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 300.

### Claim 31 (depends on 30)

The T-cell receptor according to claim 30, wherein said amino acid sequence is at least 88% identical to SEQ ID No. 1 to SEQ ID No. 300.

### Claim 32 (depends on 30)

The T-cell receptor according to claim 30, wherein said amino acid sequence consists any of SEQ ID No. 1 to SEQ ID No. 300.

### Claim 33 (depends on 30)

The T-cell receptor according to claim 30, wherein said T-cell receptor is provided as a soluble molecule and optionally carries a further effector function optionally comprising an immune stimulating domain or toxin.

### Claim 34 (depends on 30)

A nucleic acid, encoding for a TCR according to claim 30, optionally linked to a heterologous promoter sequence.

### Claim 35 (depends on 34)

An expression vector capable of expressing the nucleic acid according to claim 34.

### Claim 36 (depends on 34)

A host cell comprising the nucleic acid according to claim 34, wherein said host cell optionally is a T cell or NK cell.

### Claim 37 (depends on 30)

A method for producing the T cell receptor according to claim 30, said method comprising culturing a host cell, and isolating said T cell receptor from said host cell and/or a culture medium.

### Claim 38

A pharmaceutical composition comprising at least one active ingredient selected from the group consisting of
a) a peptide selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 300;
b) a T-cell receptor reactive with a peptide and/or the peptide-MHC complex according to a);
c) a fusion protein comprising a peptide according to a), and the N-terminal amino acids 1 to 80 of the HLA-DR antigen-associated invariant chain (Ii);
d) a nucleic acid encoding for any of a) to c) or an expression vector comprising said nucleic acid,
e) a host cell comprising the expression vector of d,
f) an activated T-lymphocyte, obtained by a method comprising contacting in vitro T cells with a peptide according to a) expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said T cell in an antigen specific manner, as well as a method to transfer these activated T cells into the autologous or other patients;
g) an antibody, or soluble T-cell receptor, reactive to a peptide and/or the peptide—MHC complex according to a) and/or a cell presenting a peptide according to a), and potentially modified by fusion with for example immune-activating domains or toxins,
h) an aptamer recognizing a peptide selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 300 and/or a complex of a peptide selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 300 with a MHC molecule,
i) a conjugated or labelled peptide or scaffold according to any of a) to h) and a pharmaceutically acceptable carrier, and optionally, pharmaceutically acceptable excipients and/or stabilizers.

### Claim 39 (depends on 1)

An aptamer that specifically recognizes the peptide or variant or salt thereof according to claim 1, optionally the peptide or variant or salt thereof is bound to an MHC molecule.

### Claim 40 (depends on 38)

A pharmaceutical composition according to claim 38, comprising at least one peptide, and optionally all peptides, selected from SEQ ID NOs 1, 2, 7, 225, 228, 301, 303 and 312.
